Maypharm Launches HYALMASS AQUATOX, a Next-Generation Multi-Active Skin Care Product
MAYPHARM, a global aesthetics and cosmeceuticals company, announced the upcoming launch of HYALMASS AQUATOX, a multi-active skin care formulation for the global market.
SEOUL, South Korea – MAYPHARM, a global aesthetics and cosmeceuticals company, has announced the upcoming market release of HYALMASS AQUATOX. The product introduces a multi-active formulation designed to address the evolving demands of the global aesthetic medicine market.
Rather than relying on a single ingredient, HYALMASS AQUATOX combines five key active components: PDRN, exosomes, botulinum peptide, GHK-Cu, and succinic acid. MAYPHARM states this formulation aims to meet the increasing global demand for multifunctional, ingredient-driven aesthetic solutions.
The launch follows growing international interest in the company's HYALMASS AQUA EXOSOME product and aims to bolster MAYPHARM's presence in the global aesthetic medicine market. Amidst increasing competition and similar product concepts, MAYPHARM emphasizes the importance of product authenticity and authorized distribution channels.
By consolidating multiple sought-after ingredients into a single product concept, MAYPHARM continues to expand its portfolio in line with emerging trends in the aesthetics industry. The company urges distributors, aesthetic medicine professionals, and consumers to verify product authenticity and authorized sales channels.